CALCIPARINE Drug Patent Profile
✉ Email this page to a colleague
When do Calciparine patents expire, and what generic alternatives are available?
Calciparine is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in CALCIPARINE is heparin calcium. There are seventy-seven drug master file entries for this compound. Additional details are available on the heparin calcium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALCIPARINE?
- What are the global sales for CALCIPARINE?
- What is Average Wholesale Price for CALCIPARINE?
Summary for CALCIPARINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | CALCIPARINE at DailyMed |
Recent Clinical Trials for CALCIPARINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris | Phase 2 |
| GlaxoSmithKline |
US Patents and Regulatory Information for CALCIPARINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | CALCIPARINE | heparin calcium | INJECTABLE;INJECTION | 018237-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
